GlassScriptPhysician profile
Norberto Mancera
NPI 1750776696
$11,206.24
in general payments reported to CMS, 2019-2025
14 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2021: $42.92 · 2022: $717 · 2023: $6,937 · 2024: $2,007 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,800 · Food and Beverage: $3,420 · Consulting Fee: $1,050 · Travel and Lodging: $917 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,800.00 |
| Food and Beverage | $3,419.77 |
| Consulting Fee | $1,050.00 |
| Travel and Lodging | $917.34 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $7,487.16 | 2021-2023 | Tepezza |
| Amgen INC. | $2,496.95 | 2024-2025 | Tepezza, Uplizna |
| Ani Pharmaceuticals, INC. | $340.53 | 2023-2024 | Purified Cortrophin Gel |
| Abbvie INC. | $195.26 | 2023-2025 | |
| Revance Therapeutics, INC. | $172.34 | 2025 | Daxxify |
| New World Medical,INC. | $148.68 | 2019 | |
| Dompe US, INC. | $113.14 | 2024 | Oxervate |
| Alcon Vision LLC | $67.35 | 2019 | |
| Bausch & Lomb Americas INC. | $57.55 | 2023-2025 | Scoutpro Osmolarity System, Miebo, Vyzulta |
| Merz Pharmaceuticals, LLC | $43.83 | 2023-2025 | Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.29 | 2019 | |
| Astellas Pharma US INC | $22.36 | 2024 | Izervay |
| Allergan, INC. | $17.92 | 2022 | |
| Oyster Point Pharma, INC. | $17.88 | 2025 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norberto Mancera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.